Methylene Blue and Postoperative Neurocognitive Disorders
Status:
Not yet recruiting
Trial end date:
2023-09-30
Target enrollment:
Participant gender:
Summary
Postoperative Neurocognitive Disorders are the most common neurological complications after
major surgery, which are associated with higher increased mortality and morbidity in elderly
patients undergoing major surgery. Until now highly effective intervention has not been
established yet. Recent preclinical studies suggest mithochiondrial dysfunction may be linked
to pathogensis of POD and POCD. As Methylene blue(MB) is a mitochondrial protective agent and
a safe drug with long history of clinical use, we propose that mitochondrial-targeted
interventions may be useful to prevent POD/POCD in elderly surgical patients.